covid anxiety causing sleepless nights8 May 2020 01:57
suggest you listen to the 2020 earnings conference call and you will nod off in no time imo. Do not even think I have got to the Q and A session at all. I think it is the monotone that imo does it for me. No proper questions asked like why was the admin expenses so high in comparison to previous year. Why does no one answer the London contact number... in which case why bother issuing it on the rns. are they aware that the receptionist is not carrying out the basic duties. Does that mean that the tea and biscuit person has also bunked off. has anyone actually frequent the London offices or were they all working remotely several years before covid19 ever appeared on the scene? Not one intellectual person even asked why the company which has a first in class respiratory drug had not looked at the prospect of using ensifenterine for covid pre admission of aftercare. How will they raise funds any one of all of the above or several of the above. Could the MDi phase 2B not start sooner..well yes it could but then do not really need it to continue phase 3. Well then why not imo save some money and ditch the trial and save what precious capital we have for phase 3. David Ebsworth must be looking forward to the dilution. Can they give us an update on what role certain members of the boards play because it seems to me that some are indeed duplicating. Why does someone not ask what value they put on ensifenterine as obviously has scared of any would be partners/buyers. Why do they not take a partner that can speed up the process to commercialization and take a bigger hit as in the long run we may get to commercialization quicker, do not know if anyone has told them that the patents only run for if I am correct another fifteen years. They maybe defunct by the time they get it marketed. Also why get expensive patents approved if commercialization comes after the patents expire. Why have they not stated the reason they have moved offices and put more meat on the bone. Try and get some positive press from it unless it is because the new CEO just lives in the neighbourhood in which case I get it. Why has such an opportunity as a major respiratory disease not helped the sp of a respiratory company, We would have done better if we produced PPE. Anyone would think Verona was an O and G explorer company not an R and D company that had a first in class respiratory drug. Is it any wonder that the sp does not rise. If this gets commercialised I reckon it would go up and stillimo manage to collapse the next day as it has done recently. It is hard to keep a straight face when discussing this share as I just want to laugh as it has been like a Comedy of Errors that knows no bounds and continues to be a total enigma imo. GLA we need that in spades. And keep safe and healthy for the next ten years and you may see it commercialise as it goes at a gravy train pace. That's a bit quicker than a snails pace. Enjoy VE day all and thanks all that gave so much. We need a WC CEO.